Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Don't expect the half of $7M in PDS licenses mentioned to hit PTSC's bottom line

Some have mentioned that they expect this last quarter to be a surprise positive. While that's possible still, I don't think we should expect that all or even some of our half of the $7M in licensing that PTSC mentioned when they released one of their recent PR's, to show up on this past quarter's financials.

Keep in mind that PTSC released this statement in the PR:

"The resolution included an agreement to provide a substantial increase in working capital for the MMP licensing program and patent infringement litigation from MMP licensing proceeds."

Essentially, they're saying that PDS will keep more money on it's balance sheet to prosecute infringement, leaving less money for the partners to split up. Based on that statement, I'd expect that all $7M will stay in the PDS coffers to cover expenses and show strength in the fight against infringers. It's possible additional licenses have been signed since that might boost the money available to the partners, but nothing more has been announced, so I wouldn't count on it. I expect a quarter not much different than the last, and only the noise around the USPTO Reexams, the T3 litigation and the relationship with TPL being more defined and more positive of late. But that's about it.

Hopefully it's enough to allow the pps to keep the small gains it's made and inch forward, but I doubt it will result in any major gains until something dramatic happens in court, or is revealed in the financials.

Share
New Message
Please login to post a reply